

**REMARKS**

A Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825.

The paper copy and computer readable copy of the Sequence Listing are the same. The Sequence Listing does not include new matter.

**CONCLUSION**

Entry of the Sequence Listing, amendments to the specification and favorable consideration are respectfully requested.

**To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.**

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Date:

*July 18, 2007*

For

*[Signature]*  
Kelli Watson Francuzenko

Registration No. 47,170

*Reg No. 39,048*

600 13<sup>th</sup> Street, N.W.

Washington, DC 20005-3096

Phone: 202.756.8000 JLT:sln

Facsimile: 202.756.8087

**Please recognize our Customer No. 20277  
as our correspondence address.**